National Advisory Council (NANDSC) Meeting - September 2019

September 04, 2019 | 12:30 - September 05, 2019 | 1:00

Contact: Kelly Baker
Contact Number: 301-496-9248
Contact Email: kelly.baker@nih.gov
Location:

National Institutes of Health (NIH)
Building 35, Porter Building
Conference Room 620/630/640
Bethesda, Maryland 20892


The 206th meeting of the National Advisory Neurological Disorders and Stroke Council will be held on Wednesday, September 4 - Thursday, September 5, 2019. For more information, visit the Advisory Council web page.
 

Related Resources

Agenda

September 4, 2019

Open Session
Time Agenda Item
12:30 p.m I.   Call to Order and Opening Remarks
       Dr. Walter Koroshetz, Chairperson
       Director, NINDS
12:35 p.m.

II.   Report of the Director, Division of Extramural Activities, NINDS
        Dr. Robert Finkelstein
       Associate Director, Division of Extramural Activities
       Executive Secretary, NANDS Council
      
       A. Consideration of Minutes of May 23-24, Meeting

       B. Confirmation of Dates for Future Council Meetings
             Wed. & Thurs., February 5-6, 2020
             Wed. & Thurs., May 27-28, 2020
             Wed. & Thurs., September 9-10, 2020
             Wed. & Thurs., February 10-11, 2021
             Wed. & Thurs., May 26-27, 2021
             Wed. & Thurs., September 8-9, 2021

       C. Other Items           
            Expedited Review Process
            Extramural Announcements

12:45 p.m.

III.   Report of the Director, NINDS
         Dr. Walter Koroshetz

1:05 p.m.

IV.   Discussion of Director’s Report 

1:20 p.m.

V.   ME/CFS Working Group Report to Council
       Dr. Andrew Breeden, Health Program Specialist, NINDS
       Dr. Steven Roberds, Chief Scientific Officer, Tuberous Sclerosis Alliance

2:05 p.m. VI.   2019 ADRD Summit Report
        Dr. Rod Corriveau, Program Director, NINDS
        Dr. Julie Schneider, The Deborah R. And Edgar D. Jannotta Presidential Professor of Pathology and Neurological Sciences,
          Associate Director, Rush Alzheimer's Disease Center, Rush University Medical Center
2:45 p.m.

BREAK

3:00 p.m.

VII.   Update from the Scientific Director of Intramural Research
          Dr. Lorna Role, Scientific Director, NINDS

4:00 p.m. VIII.   NINDS Early Stage Investigator Analysis
           Dr. William Daley, Health Program Specialist
4:30 p.m. IX.   Initiatives Requiring Concept Clearance
6:00 p.m.* Adjournment (*This time is tentative.)

 
September 5, 2019

Closed Session
Time Agenda Item
8:00 a.m.

This portion of the meeting is being closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S. Code and Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2).

X.   Review of Conflict of Interest, Confidentiality, and Council Procedures;
       Council Consideration of Pending Applications

        Dr. Robert Finkelstein
        Executive Secretary, NANDS Council

This portion of the meeting is being closed to the public in accordance with the provisions set forth in sections 552b(c)(6), Title 5, U.S. Code and Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2).

XI.   Review of the Division of Intramural Research Board of Scientific Counselors' Reports
        Dr. Walter Koroshetz, Chairperson
        Director, NINDS

1:00 p.m.* Adjournment (*This time is tentative.)

Meeting Minutes

Summary of Meeting1
 

The National Advisory Neurological Disorders and Stroke (NANDS) Council was convened for its 206th meeting on September 4-5, 2019, in the John Edward Porter Neuroscience Research Center, Building 35A, Conference Room 320/630/640 in Bethesda, Maryland. Dr. Walter Koroshetz, Director of the National Institute of Neurological Disorders and Stroke (NINDS), served as Chairperson.

In accordance with Public Law 92-463, the meeting was:

Open:      September 4, 2019: 12:30 p.m. to 6:00 p.m. for the review and discussion of program development, needs, and policy; and
Closed:    September 5, 2019: 8:30 a.m. to 12:20 p.m. for the consideration of individual grant applications.
Closed:    September 5, 2019: 12:20 p.m. to 12:50 p.m. for the review of the NINDS Intramural Research Board of Scientific Counselors’ Reports.

Council members present:
Dr. Laurence Abbott
Dr. Issam Awad
Dr. Allan Basbaum
Dr. S. Thomas Carmichael
Dr. Hollis Cline
Ms. Susan Dickinson
Dr. Nita Farahany
Dr. Aaron Gitler
Dr. David Hackney
Dr. Karen Johnston
Dr. Arnold Kriegstein
Dr. Claudia Lucchinetti
Dr. Kenneth Maynard
Ms. Eileen Murray
Dr. Indira Raman
Dr. Steve Roberds
Dr. N. Edwin Trevathan
Ms. Christin Veasley

Ex officio member present:
Colonel Sidney Hinds, II, M.D., Department of Defense
Christopher Bever, Jr., M.D., Department of Veteran Affairs

Council Roster(pdf, 116 KB)

Members of the public present for portions of the open meeting included:
Dr. Julie Schneider, Rush University Medical Center

Federal attendees are listed at the end of these minutes.

I.  Call to Order and Opening Remarks

Dr. Koroshetz welcomed Council members, visitors, and staff to the 206th meeting of the National Advisory Neurological Disorders and Stroke Council.

II.  Report of the Director, Division of Extramural Activities, NINDS

Approval of Council Minutes — Dr. Finkelstein requested, and the Council voted approval of the May 23-24, 2019, Council meeting minutes.

The following future Council meeting dates were confirmed:

Wednesday & Thursday, February 5-6, 2020
Wednesday & Thursday, May 27-28, 2020
Wednesday & Thursday, September 9-10, 2020
Wednesday & Thursday, February 10-11, 2021
Wednesday & Thursday, May 26-27, 2021
Wednesday & Thursday, September 8-9, 2021

Expedited Review Process – Each Council round, a subset of Council members approves applications in advance of the meeting with scores within the payline. This expedited review process focuses on applications for which there are no unresolved issues. Dr. Finkelstein thanked Council members Indira Raman, Susan Dickinson, and Karen Johnston for handling this responsibility for this meeting and the fiscal year. For the current Council round, 9 applications were eligible to be expedited. Nine of these awards already have been issued, and the others will be issued shortly after Council.

Extramural Announcements - Division and Office Directors presented extramural staff introductions.

III.  Report of the Director, NINDS

Dr. Walter Koroshetz, Director, NINDS

NIH and NINDS Budget — Dr. Koroshetz provided an overview of the appropriations history for NIH and NINDS. In FY 2019, NINDS received a general appropriation of $1.97 billion to support Institute operations. In addition, the Institute received $250 million for pain research as part of the Helping to End Addiction Long-term (HEAL) Initiative, $57.5 million from the 21st Century Cures Act for the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative®, and managed $170 million (10%) of the National Institute on Aging (NIA)’s appropriation for Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD). For the FY 2020 budget year, the House Markup provides NINDS with a $2 billion budget (4.4%) increase over FY 2019; however, the President's budget provides a 13% decrease. Until a final FY 2020 budget is passed, NINDS will set a payline of the 12th percentile.

NIH News — Dr. Koroshetz described the FY 2019 spending plan for the HEAL Initiative and outlined the NIH process for developing this plan. Following the review of applications submitted in response to HEAL Funding Opportunity Announcements (FOAs), project teams developed proposed funding plans which were first reviewed by the HEAL Executive Committee, comprised of Institute and Center (IC) Directors with HEAL applications in their portfolios. The Multi-Disciplinary Working Group (MDWG), a working group of multiple NIH Advisory Councils, considered the HEAL portfolio and provided input on the overall progress of HEAL toward its strategic goals. A second level of review of the HEAL funding plans, which included consideration of the input of the MDWG, was conducted by the IC Councils to develop the final HEAL funding plan.

NIH is provided funds through both the 21st Century Cures Act and through the general appropriation to support the BRAIN® Initiative. NIH anticipates receiving a total of $4.5B as part of a 10-year funding plan for BRAIN®. The NIH Advisory Committee to the Director (ACD) BRAIN 2.0 working group and neuroethics subgroup are considering priorities and strategic directions for the next phase of the BRAIN® Initiative, and they presented the draft BRAIN Initiative Working Group 2.0 and BRAIN Neuroethics reports to the ACD meeting in June.

A new NIH ACD working group has been formed to focus on foreign influences on the integrity of the U.S. biomedical research enterprise, including: the failure of investigators to disclose substantial contributions of resources from other sources, including foreign governments; the diversion of intellectual property in NIH grant applications to other entities; and the sharing of confidential information by peer reviewers with others. The activities of the NIH to address these issues have led many scientists of Chinese descent to feel unfairly targeted. Dr. Koroshetz reiterated his sensitivity to this perception and his support for this community, while stressing the importance of full disclosure of other support in NIH grant applications as described in a recently published notice (NOT-OD-19-114).

An ACD working group on NIH efforts to address sexual harassment is expected to publish a report in December. According to an Agency-wide climate survey, more than one in five NIH employees say they have experienced harassment in the past year. NIH and NINDS initiated several programs focused on demonstrating accountability, creating expectations to ensure a safe workplace, and providing clear channels of communication. To combat the cultural forces that tolerate gender harassment and limit the advancement of women, Drs. Collins and Koroshetz have announced that they will only accept speaking invitations where diversity and inclusiveness are demonstrated through the invited speaker list and agendas.

HHS Announcements — Applications submitted on or after September 25, 2019 and propose to use human fetal tissue (HFT) obtained from elective abortions will need to meet new Department of Health and Human Services (HHS) requirements and review considerations. These applications will be assessed for policy compliance by an HHS ethics advisory board composed of scientists, bioethicists, and others. NIH released a Notice on July 26, 2019 informing the research community of this change and clarified further in a second Notice released August 23, 2019.

NIH Leadership Changes — Dr. Linda Birnbaum (Director, National Institute of Environmental Health Sciences [NIEHS]) and Dr. Paul Sieving (National Eye Institute [NEI]) have retired. Dr. Koroshetz is co-chairing the NEI Director search committee.

NINDS News and Events

  • Nominations are now open for the NINDS 2020 Landis Award for Outstanding Mentorship, which rewards excellent mentors. Each year, nominations are solicited for outstanding mentors at a different career stage. In 2019, seven awards were made to faculty at the mid-career stage. NINDS is currently accepting 2020 nominations for senior faculty (researchers who are 21 years or more from the start of their first tenure track or equivalent faculty position).
  • Work on the NINDS’ strategic plan continues and a Request for Information (RFI) has been released asking for input on key questions that will inform the strategic planning process.
  • Dr. Linda Porter has been named Director of the NINDS Office of Pain Policy and Planning.
  • Upcoming events include: the International Initiative for Traumatic Brain Injury Research (InTBIR) 8th Conference (October 24–25), the Workshop on Ventricular Assist Device (VAD) Clinical Trials (November 3–4), and the HEAL Initiative Investigators Meeting (January 16–17, 2020).
  • The Accelerated Medicines Partnership: Parkinson’s Disease (AMP PD) knowledge portal
  • will house clinical and genomic data from unified Parkinson’s disease cohorts supported by NINDS, the Michael J. Fox Foundation, and the Harvard Biomarkers Study. This portal is expected to launch in the fall, and will be demonstrated at upcoming symposia and workshops.
  • Society for Neuroscience Events include a Mini-Symposium on the “BRAIN Initiative: Cutting-Edge Tools and Resources for the Community”, a NINDS-sponsored Diversity Poster Session, socials for the BRAIN® Initiative Alliance and Neuroethics, and a session on NIH funding.

Science Advances — Dr. Koroshetz summarized several recent scientific advances published by NINDS-supported investigators. The BRAIN® cell census group

used single nucleus RNA-sequencing analysis to characterize cell types isolated from post-mortem human brain cortex. They found gene expression divergence from homologous mouse cells. Another group injected synuclein fibrils into the gut wall that caused PD-like motor and non-motor symptoms. A group of researchers showed that the inverse BAR protein, Mtss1L, mediated exercise-induced enhancement of synaptic function in mice. SPRINT MIND investigators identified a significant association between intensive blood pressure control and smaller increases in cerebral white matter lesion volume. The Stroke Hyperglycemia Insulin Network Effort (SHINE) clinical trial

found that intensive versus standard control of high glucose did not improve functional outcomes in patients with acute ischemic stroke.

IV.  ME/CFS Working Group Report to Council

Dr. Steven Roberds, Chief Scientific Officer, Tuberous Sclerosis Alliance
Dr. Andrew Breeden, Health Program Specialist, NINDS

Drs. Roberds and Breeden presented a report of the NANDS Council Working Group for ME/CFS Research. ME/CFS affects immune, neurological, metabolic, and gastrointestinal systems, with symptoms that range from pain, cognitive defects, and severe exhaustion. Current estimates indicate that between 800,000 and 2.5 million people in the United States may suffer from this disorder with approximately 25% of those affected are home- or bed-bound. To address challenges of ME/CFS research, the NANDS Council Working Group for ME/CFS Research was charged with identifying research gaps and opportunities, considering strategies for NIH-supported research to attract and train a pipeline of new and young investigators for ME/CFS, and identifying potential approaches to enhance ongoing research collaborations. In March 2019, the working group issued an RFI to solicit input on how best to advance ME/CFS research; 281 responses were received, primarily from people who have ME/CFS as well as patient advocates, researchers, and healthcare providers.

The NANDSC working group presented the following recommendations:

  • Establish collaboration among federal agencies, professional organizations, and patient advocacy groups to share information, advances, and identify research gaps.
  • Expand the number of early-career researchers and researchers new to ME/CFS to enter the field by (1) increasing awareness of research opportunities; (2) promoting a multidisciplinary and collaborative approach with shared resources; and (3) involving investigators from related fields in strategic ME/CFS research planning

Next steps include dissemination of the Report of the NANDS Council Working Group for ME/CFS Research(pdf, 669 KB)(pdf, 669 KB), garnering input from stakeholders, and development of an implementation plan by the Trans-NIH ME/CFS Working Group.

Council members suggested identifying mechanisms to enhance training in the field. Members discussed the translational research component of ME/CFS and incorporating industry. Following the discussion, Council voted to approve the NANDS Council ME/CFS working group report.

V.  2019 ADRD Summit Report

Dr. Rod Corriveau, Program Director, NINDS
Dr. Julie Schneider
The Deborah R. and Edgar D. Jannotta Presidential Professor of
Pathology and Neurological Sciences
Associate Director, Rush Alzheimer's Disease Center
Rush University Medical Center

Drs. Corriveau and Schneider provided Council with a summary of the report from the NINDS-led 2019 Alzheimer’s Disease Related Dementias (ADRD) Summit, including draft research recommendations and scientific priorities. NANDS-approved research recommendations(pdf, 2131 KB)(pdf, 2131 KB) from the Summit meeting become milestones in the National Plan to Address Alzheimer’s Disease. ADRDs share cognitive and pathological features with Alzheimer’s disease and/or commonly co-occur with typical Alzheimer’s pathology. They include frontotemporal dementia (FTD), Lewy Body Dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), and mixed dementias or multiple etiology dementias (MED). Some examples of high-priority recommendations that emerged from the Summit include:

  • Objective detection of cognitive impairment when reported by a patient, care partner, or clinician reports cognitive, behavioral, or functional changes.
  • Advancement of basic and clinical research on common mechanisms of multi-etiology cognitive impairment and dementia.
  • Generation and/or improvement of cognitive assessment tools for AD/ADRD health disparity populations.
  • Clarification of cellular and converging cellular mechanisms contributing to FTD neurodegeneration.
  • Development of experimental models and translational imaging methods for VCID.
  • Development of biomarker/risk profiles to establish in vivo diagnostic criteria for TDP-43 pathology.
  • Encouragement of cross-talk and interdisciplinary collaboration between traumatic brain injury and dementia researchers.

Council members discussed the critical contribution of biomarkers, artificial intelligence/machine learning and clinical trials as part of the AD/ADRD Initiatives. Following discussion, Council voted to approve the report.

VI.  Update from the Scientific Director of Intramural Research

Dr. Lorna Role, Scientific Director, NINDS

Dr. Role presented an overview of the NINDS Intramural Research Program (IRP), highlighting that rather than supporting specific research projects, the IRP supports investigators, enabling risk-taking through stable funding and flexibility. In addition, Dr. Role noted the tremendous opportunities for collaboration and training in the IRP, as well as the unique resources and scientific opportunities provided by the NIH Clinical Center.

Approximately 50 investigators are part of the NINDS IRP, and these investigators were cited in over 400 journal articles published in 2018. Several examples of some of the cutting-edge work conducted in the IRP was highlighted, including: Dr. Kareem Zaghloul’s work using intracranial EEG recordings to demonstrate brain electrophysiological coupling activity during associative learning; Dr. Zu-Hang Sheng’s work, clarifying syntaphilin’s role in regulating mitochondrial transport in neurons; and Dr. Antonina Roll-Mecak’s studies using cryo-EM to describe the structure of the microtubulin protein spastin and the mutations in this protein that are present in patients with hereditary spastic paraplegias.

Lastly, Dr. Role described her overall priorities for the NINDS IRP including: fostering a supportive work environment that ensures diversity and inclusiveness at all levels, strengthening both fundamental and clinical neuroscience research and their interactions, upgrading NINDS core facilities to enable new research directions and collaborations, and enhancing research training in the IRP.

VII. NINDS Early Stage Investigator Analysis

Dr. William Daley, Health Program Specialist, NINDS

Dr. Daley described NINDS’ support for ESIs and the future success of these PIs following the completion of their ESI award. An ESI is defined by NIH as a PI who has completed his/her terminal research degree or medical residency within the past ten years and has not successfully competed for a substantial NIH grant. Under the Next Generation Researchers’ policy, meritorious R01-equivalent applications from ESI PIs are prioritized for funding. NINDS has had policies in place for the past 10 years to support ESIs past the payline, and currently supports most ESI R01s 10 points past the payline, up to the 25th percentile. Dr. Daley employed a cohort approach to compare R01 funding from ESIs supported through the general payline with those supported through the extended payline. Results from this analysis suggest that extended payline ESIs do at least as well as general payline ESIs, with some extended payline ESIs doing better than general payline ESIs. Further study shows no correlation between extended payline success and fellowships, career development awards, or pre-ESI R01 applications/awards. Preliminary data shows a trend that the PIs funded through the extended payline resubmit for their next R01 sooner compared to the ESIs within the normal payline.

Council discussed other possible measures to assess the outcomes of ESIs in the extended payline range such as publications, mentorship and scores on subsequent submissions.

VIII. Initiatives Requiring Concept Clearance

1) Research Resources Cores for Emerging Neuroscience Programs

Dr. Timothy LaVaute, Program Director, NINDS

At the 201901 meeting of the NANDS Council, a concept was presented to direct funding of neurotechnology infrastructure toward emerging neuroscience programs. Incorporating the recommendations from the NANDS Council, Dr. LaVaute presented a revised concept to provide high-quality research resource cores to institutions with emerging neuroscience programs.

Council discussed the metrics for measuring the impact of the cores at the Institution such as publications or grant submissions that cite the core. Council discussed opportunities for collaborations with start-ups created by scientists that may have moved outside of academia. Small businesses could have access to the Institutional core. Council recommended adding this form of collaboration to the program announcement.

Council voted to approve the proposed concept.

Dr. Finkelstein presented three Initiatives that are being reissued and conveyed to the Council members that as reissues, a formal Council vote is not obligatory, but input and comments are welcome. The renewal Initiative are:

  1. BRAIN Initiative: Biology and Biophysics of Neural Stimulation and Recording Technologies (R01 Clinical Trials Optional)
  2. Blueprint Neurotherapeutics Network
  3. NINDS’ Neuroscience Development for Advancing Careers of Diverse Research Workforce

IX. Council Consideration of Pending Applications

This portion of the meeting, involving specific grant review, was closed to the public. The Council gave special attention to applications from foreign institutions and other applications requiring specific discussion. Prior to discussion of the grants, Dr. Finkelstein reminded Council members regarding conflict of interest and confidentiality.

Conflict of Interest — Regulations concerning conflict of interest were reviewed. Council members were reminded that materials furnished for review purposes and discussion during the closed portions of the meeting are considered privileged information. All Council members present signed a statement certifying that they had not been involved in any conflict-of-interest situations during the review of grant applications.

Confidentiality — During the closed session, any information that is discussed and the outcome of any recommendation are considered privileged information. They may not be discussed outside of the closed session. If an applicant requests support for his or her application from a Council member, the Council member must respond that he/she is not permitted to discuss the application. Any inquiry should be referred to Dr. Robert Finkelstein, NINDS Advisory Council Executive Secretary, who then will refer the question to the appropriate staff member for response.

Research Training and Career Development Programs – The Council reviewed a total of 324 research career development and institutional training grant applications with primary assignment to NINDS, and 226 of them (70 percent) were scored in the amount of $19.8 million first-year direct costs. It is anticipated that, of the research career development and institutional training grant applications competing at this Council, NINDS will be able to pay first-year direct costs of approximately $9.5 million (114 grants).

Research Project and Center Awards – The Council reviewed a total of 1,750 research project and center applications with primary assignment to NINDS, and 990 of them (57 percent) were scored/percentiled in the amount of $388.9 million first-year direct costs. It is anticipated that, of the research grants competing at this Council, NINDS will be able to pay first-year direct costs of approximately $68.8 million (215 grants).

Senator Jacob Javits Neuroscience Investigator Awards – The Senator Jacob Javits Neuroscience Investigator Awards are made to distinguished investigators who have a record of scientific excellence and productivity, who are actively pursuing an area of research of strategic importance, and who can be expected to continue to be highly productive for a seven-year period. Candidates are nominated and selected at each Council meeting. Council approved one Javits nomination at this meeting: Thomas L. Schwarz, Ph.D. (Boston Children’s Hospital).

Small Business Innovation Research and Small Business Technology Transfer Award Programs – The Council reviewed a total of 173 Small Business Innovation Research (SBIR) and Small Technology Transfer Award (STTR) grant applications with primary assignment to NINDS, and 89 of them (51 percent) were scored in the amount of $35.4 million first-year direct costs. It is anticipated that, of the SBIR and STTR applications competing at this Council, NINDS will be able to pay first-year direct costs of approximately $5.4 million (17 grants).

X.  Review of the Division of Intramural Research Board of Scientific Counselors’ Reports

Dr. Lorna Role, Scientific Director, Division of Intramural Research, NINDS

This portion of the meeting, to review and evaluate the Division of Intramural Research Board of Scientific Counselors’ Reports, was closed to the public.

IX.  Adjournment

The meeting was adjourned at 12:50 p.m. on Thursday, September 5, 2019.

NINDS employees present for portions of the meeting included:

Dr. Amy Adams
Dr. DeAnna Adkins
Dr. Deborah Babcock
Dr. Julia Bachman
Ms. Kelly Baker
Dr. Patrick Bellgowan
Dr. Francesca Bosetti
Dr. Andrew Breeden
Mr. Ryan Calabrese
Dr. Emily Carifi
Ms. Stacey Chambers
Ms. Janice Cordell
Dr. Roderick Corriveau
Dr. Diana Cummings
Dr. Charles Cywin
Dr. William Daley
Dr. Tia Decoster
Dr. Argenia Doss
Dr. Kristin Dupre
Ms. Debbie Eng
Dr. Carlos Faraco
Ms. Stephanie Fertig
Dr. Robert Finkelstein
Dr. Jane Fountain
Mr. Peter Gilbert
Mr. Paul Girolami
Ms. Ashley Givens
Dr. Brooks Gross
Dr. Amelie Gubitz
Dr. Mohamed Hachicha
Mr. Brandon Hartsell
Dr. Rebecca Hommer
Dr. Nina Hsu
Dr. Lyn Jakeman
Dr. Scott Janis
Dr. Li Jia
Dr. Li Jiang
Dr. Michelle Jones-London
Dr. Barbara Karp
Dr. Brian Klein
Dr. Jim Koenig
Dr. Walter Koroshetz
Dr. Sahana Kukke
Dr. Doe Kumsa
Ms. Christine Lam
Dr. Nick Langhals
Dr. Timothy LaVaute
Dr. Miriam Leenders
Dr. Codrin Lungu
Ms. Quynh Ly
Dr. Marguerite Matthews
Dr. Linda McGavern
Ms. Barbara McMakin
Dr. Carolina Mendoza-Puccini
Dr. Daniel Miller
Dr. DP Mohapatra
Dr. Claudia Moy
Dr. Glen Nuckolls
Dr. Ana Olariu
Mrs. Oreisa O’Neil
Dr. Michael Oshinsky
Dr. David Owens
Dr. Mary Ann Pelleymounter
Dr. Leah Pogorzala
Dr. Shamsi Raeissi
Dr. Shanta Rajaram
Dr. Khara Ramos
Dr. Nagarajan Rangarajan
Dr. K. Paul Rezaizadeh
Dr. Robert Riddle
Dr. Lorna Role
Dr. Becky Roof
Dr. Jonathan Sabbagh
Dr. Cheryse Sankar
Dr. Cristina Saugar-Lanchas
Dr. Alisa Schaefer
Dr. Nina Schor
Dr. Paul Scott
Ms. Hawa Sesay
Ms. Shalini Sharma
Dr. Beth-Anne Sieber
Dr. Shardell Spriggs
Dr. Natalia Strunnikova
Dr. Christine Swanson-Fischer
Dr. Ned Talley
Dr. Amir Tamiz
Dr. Anna Taylor
Dr. Carol Taylor-Burds
Dr. Michael Tennekoon
Dr. Christine Torborg
Dr. Lauren Ullrich
Dr. Ursula Utz
Dr. Joanna Vivalda
Dr. Jackie Ward
Dr. Laura Wandner
Ms. Margo Warren
Dr. Letita Weigand
Dr. Samantha White
Dr. Vicky Whittemore
Dr. Sarah Woller
Dr. May Wong
Dr. Ling Wong
Dr. Clinton Wright
Dr. Ye Yan
Dr. Robert Zalutsky

Other federal employees present for portions of the meeting included:

Dr. Joseph Breen, NIAID
Dr. Peter Guthrie, CSR
Dr. Carole Jelsema, CSR
Dr. Linda MacArthur, CSR
Dr. Laurent Taupenot, CSR

Non-federal present for portions of the meeting included:

Dr. Catherina Krebs, Physicians Committee for Responsible Medicine

We certify that, to the best of our knowledge, the foregoing minutes and attachments are accurate and complete.

 

______
Date

_____________________________
Robert Finkelstein, Ph.D.
Executive Secretary
National Advisory Neurological Disorders
and Stroke Council

Director, Division of Extramural Research
National Institute of Neurological Disorders
and Stroke

______
Date
_____________________________
Walter Koroshetz, M.D.
Chairperson
National Advisory Neurological Disorders
and Stroke Council

Director
National Institute of Neurological Disorders
and Stroke

These minutes will be formally considered by the Council at its next meeting. Corrections or notations will be incorporated in the minutes of that meeting.


1For the record, it is noted that members absent themselves from the meeting when the Council is discussing applications (a) from their respective institutions or (b) in which a real or apparent conflict of interest might occur.